Roger Jeffs is Co-Founder and Vice Chairman at Kriya Therapeutics. Dr. Jeffs was the President and co-CEO of United Therapeutics Corporation, joining the company during its start-up phase in 1998. He helped lead the company's IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial efforts that led to a $1.5B annual revenue run rate. He currently serves on the boards of Axsome Therapeutics, Albireo Pharma and Liquidia Corporation. He previously served on the boards of United Therapeutics, Sangamo Therapeutics, and Dova Pharmaceuticals.
Dr. Jeffs received his Ph.D. in pharmacology from the University of North Carolina School of Medicine and his undergraduate degree in chemistry from Duke University.